2025-01-14 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**1. Performance Comparison & Divergence:**

Johnson & Johnson (JNJ), a diversified healthcare company producing medical devices, pharmaceuticals, and consumer goods, has significantly underperformed the S&P 500 (VOO) over the given period.  While JNJ shows a cumulative return of 23.31%, VOO boasts a return of 112.47%. This represents a substantial divergence of -89.2%, placing it at the 8.4th percentile of its historical range compared to the S&P 500.  The provided alpha consistently hovers around zero, indicating the stock's performance largely mirrors the market (beta is not consistently provided, hindering a more precise assessment).  While past CAGR figures show periods of strong growth, the recent trend reveals considerable underperformance.  The high negative CAGR in recent years (-11%, -25%, -16%) clearly illustrates the challenges JNJ has faced.


**2. Recent Price Movement:**

* **Closing Price:** $144.47
* **5-Day Moving Average:** $143.74
* **20-Day Moving Average:** $144.63
* **60-Day Moving Average:** $151.94

The price is currently slightly below its 20-day moving average and significantly below its 60-day moving average, suggesting a downtrend.


**3. Technical Indicators & Expected Return:**

* **RSI:** 52.7 – Suggests neither overbought nor oversold conditions.
* **PPO:** 0.16 – A slightly positive value indicating potential bullish momentum, but weak.
* **Relative Strength Change (20-day):** +3.5 – Shows short-term upward momentum, though weak.
* **Expected Return (2+ years):** -298.9% – This extremely negative projected return relative to the S&P 500 needs further clarification.  Such a dramatic negative figure is highly unusual and warrants scrutiny of the methodology used to arrive at this projection.  It may be based on assumptions not explicitly stated. The given closing price does not represent a significant jump or drop to necessitate a comment on this element.

**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
|------------|-------|---------------|
| 2024-10-23 | $1.12 | $22.47B       |
| 2024-07-25 | $1.95 | $22.45B       |
| 2024-05-01 | $1.35 | $21.38B       |
| 2024-02-16 | $1.68 | $21.39B       |
| 2023-10-27 | $10.32| $21.35B       |

The EPS figures show significant volatility, with a surprisingly high EPS of $10.32 in October 2023.  This needs further investigation to understand the underlying factors. Revenue remains relatively stable around the $21-22B range.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue      | Profit Margin |
|---------|---------------|---------------|
| 2024-09-30 | $22.47B       | 69.01%        |
| 2024-06-30 | $22.45B       | 69.40%        |
| 2024-03-31 | $21.38B       | 69.55%        |
| 2023-12-31 | $21.39B       | 68.23%        |
| 2023-09-30 | $21.35B       | 69.06%        |

Revenue is relatively consistent.  Profit margins are high and stable, suggesting strong operational efficiency.

**Capital and Profitability:**

| Quarter | Equity       | ROE           |
|---------|---------------|---------------|
| 2024-09-30 | $70.16B       | 3.84%         |
| 2024-06-30 | $71.54B       | 6.55%         |
| 2024-03-31 | $70.02B       | 4.65%         |
| 2023-12-31 | $68.77B       | 5.89%         |
| 2023-09-30 | $71.23B       | 36.54%        |


Equity fluctuates slightly.  ROE shows considerable variation, with an exceptionally high value of 36.54% in Q3 2023, again warranting further investigation.


**7. Overall Analysis:**

JNJ's recent performance has been disappointing compared to the broader market. While the company maintains strong profitability and stable revenue, the significant underperformance against the S&P 500, the volatile EPS figures, and particularly the exceptionally high ROE in one quarter, all raise concerns.  The extremely negative projected long-term return (-298.9%) is highly suspect and requires a thorough review of its calculation.  Further investigation into the causes of the erratic EPS and ROE figures is crucial before making any investment decisions.  The current technical indicators suggest a neutral to slightly positive short-term outlook, but the longer-term picture warrants cautious consideration.  Additional due diligence is highly recommended before investing.


**8. Disclaimer:** This analysis is based on the provided data and is for informational purposes only. It is not financial advice.  Investment decisions should be based on thorough research and consultation with a qualified financial advisor.  The validity of the -298.9% expected return figure is questionable and should be independently verified.
